Follow
Vinayak Singh
Vinayak Singh
Senior Research Officer, Drug Discovery & Development Centre (H3D), University of Cape Town
Verified email at uct.ac.za
Title
Cited by
Cited by
Year
Strategies to combat multi-drug resistance in tuberculosis
V Singh, K Chibale
Accounts of chemical research 54 (10), 2361-2376, 2021
952021
The complex mechanism of antimycobacterial action of 5-fluorouracil
V Singh, M Brecik, R Mukherjee, JC Evans, Z Svetlíková, J Blaško, ...
Chemistry & biology 22 (1), 63-75, 2015
942015
The inosine monophosphate dehydrogenase, GuaB2, is a vulnerable new bactericidal drug target for tuberculosis
V Singh, S Donini, A Pacitto, C Sala, RC Hartkoorn, N Dhar, G Keri, ...
ACS infectious diseases 3 (1), 5-17, 2017
892017
Detection of Mycobacterium tuberculosis bacilli in bio-aerosols from untreated TB patients
B Patterson, C Morrow, V Singh, A Moosa, M Gqada, J Woodward, ...
Gates open research 1, 2017
852017
Identification and validation of novel drug targets in Mycobacterium tuberculosis
V Singh, V Mizrahi
Drug Discovery Today 22 (3), 503-509, 2017
752017
Drug-resistance in Mycobacterium tuberculosis: where we stand
A Mabhula, V Singh
Medchemcomm 10 (8), 1342-1360, 2019
732019
A fragment-based approach to targeting inosine-5´-monophosphate dehydrogenase (IMPDH) from Mycobacterium tuberculosis
CA Ana Trapero, Angela Pacitto, Vinayak Singh, Mohamad Sabbah, Anthony G ...
J. Med. Chem., 2018
602018
Neurological consequences of SARS-CoV-2 infection and concurrence of treatment-induced neuropsychiatric adverse events in COVID-19 patients: navigating the uncharted
P Borah, PK Deb, B Chandrasekaran, M Goyal, M Bansal, S Hussain, ...
Frontiers in molecular biosciences 8, 627723, 2021
512021
Real-time investigation of tuberculosis transmission: developing the respiratory aerosol sampling chamber (RASC)
R Wood, C Morrow, CE Barry III, WA Bryden, CJ Call, AJ Hickey, ...
PloS one 11 (1), e0146658, 2016
502016
The quest for the holy grail: new antitubercular chemical entities, targets and strategies
S Huszar, K Chibale, V Singh
Drug Discovery Today 25 (4), 772-780, 2020
462020
Perspectives on RNA vaccine candidates for COVID-19
P Borah, PK Deb, NA Al-Shar’i, LA Dahabiyeh, KN Venugopala, V Singh, ...
Frontiers in Molecular Biosciences 8, 635245, 2021
392021
Expanding benzoxazole-based inosine 5′-monophosphate dehydrogenase (IMPDH) inhibitor structure–activity as potential antituberculosis agents
S Chacko, HIM Boshoff, V Singh, DM Ferraris, DR Gollapalli, M Zhang, ...
Journal of medicinal chemistry 61 (11), 4739-4756, 2018
372018
Current advances in the clinical development of anti-tubercular agents
SR Tetali, E Kunapaeddi, RP Mailavaram, V Singh, P Borah, PK Deb, ...
Tuberculosis 125, 101989, 2020
352020
Biochemical and transcription analysis of acetohydroxyacid synthase isoforms in Mycobacterium tuberculosis identifies these enzymes as potential targets for drug …
V Singh, D Chandra, BS Srivastava, R Srivastava
Microbiology 157 (1), 29-37, 2011
352011
Predictive modeling targets thymidylate synthase ThyX in Mycobacterium tuberculosis
K Djaout, V Singh, Y Boum, V Katawera, HF Becker, NG Bush, ...
Scientific reports 6 (1), 27792, 2016
332016
Downregulation of Rv0189c, encoding a dihydroxyacid dehydratase, affects growth of Mycobacterium tuberculosis in vitro and in mice
V Singh, D Chandra, BS Srivastava, R Srivastava
Microbiology 157 (1), 38-46, 2011
302011
Current scenario and future prospect in the management of COVID-19
P Borah, PK Deb, S Deka, KN Venugopala, V Singh, RP Mailavaram, ...
Current medicinal chemistry 28 (2), 284-307, 2021
262021
Hit discovery of Mycobacterium tuberculosis inosine 5′-monophosphate dehydrogenase, GuaB2, inhibitors
NU Sahu, V Singh, DM Ferraris, M Rizzi, PS Kharkar
Bioorganic & medicinal chemistry letters 28 (10), 1714-1718, 2018
262018
Developing synergistic drug combinations to restore antibiotic sensitivity in drug-resistant Mycobacterium tuberculosis
C Omollo, V Singh, E Kigondu, A Wasuna, P Agarwal, A Moosa, ...
Antimicrobial agents and chemotherapy 65 (5), 10.1128/aac. 02554-20, 2021
242021
Tuberculosis: an update on pathophysiology, molecular mechanisms of drug resistance, newer anti-TB drugs, treatment regimens and host-directed therapies
P Borah, PK Deb, KN Venugopala, NA Al-Shar'i, V Singh, S Deka, ...
Current Topics in Medicinal Chemistry 21 (6), 547-570, 2021
242021
The system can't perform the operation now. Try again later.
Articles 1–20